Safety of guselkumab in patients with psoriatic arthritis through 1 year: Pooled findings from DISCOVER-1 and DISCOVER-2 phase 3 trials

被引：0
|
作者：
Ritchlin, Christopher T. [1 ]
Rahman, Proton [2 ]
Helliwell, Philip S. [3 ]
Boehncke, Wolf-Henning [4 ]
McInnes, Iain [5 ]
Gottlieb, Alice B. [6 ]
Kollmeier, Alexa P. [7 ]
Shawi, May [8 ]
Zhou, Bei [7 ]
Mease, Philip J. [9 ]
机构：
[1] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[2] Mem Univ Newfoundland, St John, NF, Canada
[3] Univ Leeds, Leeds, W Yorkshire, England
[4] Geneva Univ Hosp, Geneva, Switzerland
[5] Univ Glasgow, Glasgow, Lanark, Scotland
[6] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA
[7] Janssen Res & Dev LLC, Raritan, NJ USA
[8] Janssen Global Serv LLC, Raritan, NJ USA
[9] Univ Washington, Swedish Med Ctr, Providence St Joseph Hlth, Seattle, WA 98195 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27529
引用
收藏
页码：AB151 / AB151
页数：1
相关论文
共 50 条
  • [31] GUSELKUMAB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENTS IN GENERAL HEALTH OUTCOMES MEASURED WITH PROMIS-29 THROUGH 52 WEEKS: RESULTS FROM THE PHASE 3 DISCOVER-1 TRIAL
    Orbai, A. M.
    Coates, L. C.
    Deodhar, A.
    Helliwell, P.
    Ritchlin, C. T.
    Kollmeier, A.
    Hsia, E. C.
    Xu, X. L.
    Sheng, S.
    Jiang, Y.
    Liu, Y.
    Han, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 785 - 786
  • [32] Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
    Mease, Philip J.
    Gladman, Dafna D.
    Poddubnyy, Denis
    Chakravarty, Soumya D.
    Shawi, May
    Kollmeier, Alexa P.
    Xu, Xie L.
    Xu, Stephen
    Deodhar, Atul
    Baraliakos, Xenofon
    RHEUMATOLOGY AND THERAPY, 2023, 10 (06) : 1637 - 1653
  • [33] The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
    Jeffrey R. Curtis
    Iain B. McInnes
    Proton Rahman
    Dafna D. Gladman
    Steven Peterson
    Prasheen Agarwal
    Feifei Yang
    Alexa P. Kollmeier
    Elizabeth C. Hsia
    Natalie J. Shiff
    Bei Zhou
    Chenglong Han
    May Shawi
    William Tillett
    Philip J. Mease
    Advances in Therapy, 2022, 39 : 4613 - 4631
  • [34] Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
    Philip J. Mease
    Dafna D. Gladman
    Denis Poddubnyy
    Soumya D. Chakravarty
    May Shawi
    Alexa P. Kollmeier
    Xie L. Xu
    Stephen Xu
    Atul Deodhar
    Xenofon Baraliakos
    Rheumatology and Therapy, 2023, 10 : 1637 - 1653
  • [35] The Effect of Guselkumab on General Health State in Biologic-Naive Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
    Curtis, Jeffrey R.
    McInnes, Iain B.
    Rahman, Proton
    Gladman, Dafna D.
    Yang, Feifei
    Peterson, Steven
    Agarwal, Prasheen
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Han, Chenglong
    Shiff, Natalie J.
    Shawi, May
    Tillett, William
    Mease, Philip J.
    ADVANCES IN THERAPY, 2022, 39 (10) : 4632 - 4644
  • [36] The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
    Jeffrey R. Curtis
    Iain B. McInnes
    Proton Rahman
    Dafna D. Gladman
    Feifei Yang
    Steven Peterson
    Prasheen Agarwal
    Alexa P. Kollmeier
    Elizabeth C. Hsia
    Chenglong Han
    Natalie J. Shiff
    May Shawi
    William Tillett
    Philip J. Mease
    Advances in Therapy, 2022, 39 : 4632 - 4644
  • [37] GUSELKUMAB DEMONSTRATED AN INDEPENDENT TREATMENT EFFECT ON FATIGUE AFTER ADJUSTMENT FOR CLINICAL RESPONSE (ACR20) IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM PHASE-3 TRIALS DISCOVER 1 & 2
    Helliwell, P.
    Rahman, P.
    Deodhar, A.
    Kollmeier, A.
    Hsia, E. C.
    Zhou, B.
    Lin, X.
    Han, C.
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1160 - 1160
  • [38] Impact of guselkumab on fatigue and mediation analysis of independent treatment effect of guselkumab on fatigue in patients with active psoriatic arthritis: Results from DISCOVER-1&2
    Rahman, Proton
    Helliwell, Philip S.
    Deodhar, Atul
    Kollmeier, Alexa P.
    Hsia, Elizabeth
    Zhou, Bei
    Lin, Xiwu
    Han, Chenglong
    Yang, Ya-Wen
    Mease, Philip J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB153 - AB153
  • [39] Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from DISCOVER 1&2 and PSUMMIT Trials
    Diels, Joris
    Thilakarathne, Pushpike
    Schubert, Agata
    Hassan, Fareen
    Peterson, Steven
    Noel, Wim
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3692 - 3693
  • [40] FOUR-YEAR EFFICACY AND SAFETY OF GUSELKUMAB IN PSORIASIS PATIENTS WITH AND WITHOUT PSORIATIC ARTHRITIS: A POOLED ANALYSIS FROM VOYAGE 1 AND VOYAGE 2
    Reich, K.
    Dutz, J.
    Foley, P.
    Thaci, D.
    Vender, R.
    Song, M.
    Miller, M.
    You, Y.
    Li, S.
    Shen, Y. K.
    Armstrong, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1673 - 1673
12345